|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Bellicum Pharmaceuticals, Inc (BLCM) |
|
|
$0.07 0.00 (0.00%) as of 4:30 Mon 3/4
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
6,100,000 |
| Market
Cap: |
455.98(K) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.0745 - $0.96 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Bellicum Pharmaceuticals is a biopharmaceutical company focused on discovering and developing controllable cellular immunotherapies for the treatment of various forms of cancer. Co. is developing chimeric antigen receptors (CAR)-T cell therapies, which are an approach in which a patient's or donor's T cells are genetically modified to carry CARs. By incorporating its switch technologies, Co. is developing product candidates in various areas of cellular immunotherapy including BPX-601, which is designed to treat solid tumors expressing prostate stem cell antigen; and BPX-603, which is designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Foster Aaron E. |
Sr VP, Head of Research |
• – – |
2020-01-03 |
4 |
D |
$1.40 |
$330 |
D/D |
(236) |
7,281 |
|
- |
|
| Foster Aaron E. |
Sr VP, Head of Research |
• – – |
2020-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
625 |
7,517 |
|
- |
|
| Smith Alan K. |
EVP, Technical Operations |
• – – |
2020-01-03 |
4 |
D |
$1.40 |
$825 |
D/D |
(589) |
6,956 |
|
- |
|
| Smith Alan K. |
EVP, Technical Operations |
• – – |
2020-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,563 |
7,545 |
|
- |
|
| Williams Rosemary Y. |
VP, Finance & PAO |
• – – |
2020-01-02 |
4 |
D |
$1.51 |
$729 |
D/D |
(483) |
5,270 |
|
- |
|
| Williams Rosemary Y. |
VP, Finance & PAO |
• – – |
2020-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,282 |
5,753 |
|
- |
|
| Foster Aaron E. |
Sr VP, Head of Research |
• – – |
2020-01-02 |
4 |
D |
$1.51 |
$1,422 |
D/D |
(942) |
6,892 |
|
- |
|
| Foster Aaron E. |
Sr VP, Head of Research |
• – – |
2020-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
7,834 |
|
- |
|
| Smith Alan K. |
EVP, Technical Operations |
• – – |
2020-01-02 |
4 |
D |
$1.51 |
$1,333 |
D/D |
(883) |
5,982 |
|
- |
|
| Smith Alan K. |
EVP, Technical Operations |
• – – |
2020-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,344 |
6,865 |
|
- |
|
| Woodard Jr Joseph Paul |
SVP Clinical & Medical Affairs |
• – – |
2019-11-13 |
4 |
D |
$0.82 |
$1,310 |
D/D |
(1,597) |
5,467 |
|
- |
|
| Woodard Jr Joseph Paul |
SVP Clinical & Medical Affairs |
• – – |
2019-11-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,750 |
7,064 |
|
- |
|
| Fair Richard A. |
President and CEO |
• • – |
2019-09-10 |
4 |
B |
$1.25 |
$50,000 |
D/D |
40,000 |
66,561 |
2.81 |
- |
|
| Ward Shane |
Sr. VP and General Counsel |
• – – |
2019-08-29 |
4 |
B |
$1.23 |
$9,822 |
D/D |
8,000 |
18,294 |
2.74 |
- |
|
| Fair Richard A. |
President and CEO |
• • – |
2019-08-21 |
4 |
B |
$0.99 |
$19,780 |
D/D |
20,000 |
26,561 |
2.81 |
- |
|
| Naeve Gregory S. |
Chief Business Officer |
• – – |
2019-08-21 |
4 |
D |
$0.95 |
$1,513 |
D/D |
(1,597) |
13,746 |
|
- |
|
| Ward Shane |
Sr. VP and General Counsel |
• – – |
2019-05-29 |
4 |
D |
$2.09 |
$2,226 |
D/D |
(1,065) |
8,935 |
|
- |
|
| Foster Aaron E. |
Sr VP, Head of ResearchOfficer |
• – – |
2019-02-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,737 |
|
- |
|
| Grossman William |
Sr. VP, Chief Medical Officer |
• – – |
2019-02-05 |
4 |
D |
$3.48 |
$10,878 |
D/D |
(3,126) |
26,874 |
|
- |
|
| Spencer David M. |
Chief Technology Officer |
• – – |
2019-01-03 |
4 |
D |
$3.20 |
$1,885 |
D/D |
(589) |
92,470 |
|
- |
|
| Spencer David M. |
Chief Technology Officer |
• – – |
2019-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,562 |
93,059 |
|
- |
|
| Smith Alan K. |
EVP, Technical Operations |
• – – |
2019-01-03 |
4 |
D |
$3.20 |
$1,885 |
D/D |
(589) |
4,521 |
|
- |
|
| Smith Alan K. |
EVP, Technical Operations |
• – – |
2019-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,562 |
5,110 |
|
- |
|
| Williams Rosemary Y. |
Principal Accounting Officer |
• – – |
2019-01-03 |
4 |
D |
$3.20 |
$944 |
D/D |
(295) |
4,471 |
|
- |
|
| Williams Rosemary Y. |
Principal Accounting Officer |
• – – |
2019-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
782 |
4,766 |
|
- |
|
179 Records found
|
|
Page 2 of 8 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
